Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | KLK11 |
| Gene Name: | KLK11 |
| Alias: | Hippostasin;Serine protease 20;Trypsin-like protease |
| Mass (Da): | 31059 |
| Number AA: | 282 |
| UniProt ID: | Q9UBX7 |
| Locus ID: | 11012 |
| COSMIC ID: | KLK11 |
| Gene location on chromosome: | 19q13.41 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.26 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | KLK11 is a secreted protease of the kallikrein family. It has been suggested to be implicated in carcinogenesis , but its mechanism of action in cancer is unknown. Higher expression levels have been associated with higher tumour grade, stage, and Gleason score in testicular cancer, but better prognosis in ovarian tumors and non-small cell lung cancer. It was hypothesized that KLK11 may facilitate the release of IGF by degrading IGF binding protein 3, an inhibitor of IGF. |